Correlation of Serum Magnesium with Dyslipidemia in Maintenance Hemodialysis Patients

Impact of Post-Transplantation Hypomagnesemia on Long-Term Graft and Patient Survival after Transplantation

BACKGROUND

Post-transplant hypomagnesemia is commonly observed among patients prescribed calcineurin inhibitor (CNIs).

METHODS

We conducted a retrospective single-center analysis (2000-2013, N = 726) to examine the association of hypomagnesemia with long-term patient and allograft outcomes in kidney transplant recipients. A median serum magnesium (Mg) level of all measured Mg levels from 1 month to 1 year posttransplant was calculated.

RESULTS

For every increase in Mg of 0.1 mg/dL, the risk for either graft loss or death, overall mortality, and death with a functioning graft increased by 11%, 14%, and 12%, respectively (p < 0.01). In a multivariate model, patients with median Mg level ≥1.7 mg/dL had a reduced overall survival rate (HR 1.57, 95% CI: 1.04-2.38, p = 0.033) compared to those with median Mg level <1.7 mg/dL. This association was observed in subgroups of patients above 60 years old, in those who had a slow graft function (SGF) and in females.

CONCLUSIONS

Posttransplant hypomagnesemia is associated with better patient and allograft survival up to 10 years posttransplant. This relationship remained significant after accounting for baseline allograft function, presence of SGF and CNI trough levels.

Crosstalk of Magnesium and Serum Lipids in Dyslipidemia and Associated Disorders: A Systematic Review

Dyslipidemia is a significant threat to public health worldwide and the identification of its pathogenic mechanisms, as well as novel lipid-lowering agents, are warranted. Magnesium (Mg) is a key element to human health and its deficiency has been linked to the development of lipid abnormalities and related disorders, such as the metabolic syndrome, type 2 diabetes mellitus, or cardiovascular disease. In this review, we explored the associations of Mg (dietary intake, Mg concentrations in the body) and the lipid profile, as well as the impact of Mg supplementation on serum lipids. A systematic search was computed in PubMed/MEDLINE and the Cochrane Library and 3649 potentially relevant papers were detected and screened (n = 3364 following the removal of duplicates). After the removal of irrelevant manuscripts based on the screening of their titles and abstracts (n = 3037), we examined the full-texts of 327 original papers. Finally, after we applied the exclusion and inclusion criteria, a number of 124 original articles were included in this review. Overall, the data analyzed in this review point out an association of Mg concentrations in the body with serum lipids in dyslipidemia and related disorders. However, further research is warranted to clarify whether a higher intake of Mg from the diet or via supplements can influence the lipid profile and exert lipid-lowering actions.

Modeling the risk factors for dyslipidemia and blood lipid indices: Ravansar cohort study

BACKGROUND

Lipid disorder is one of the most important risk factors for chronic diseases. Identifying the factors affecting the development of lipid disorders helps reduce chronic diseases, especially Chronic Heart Disease (CHD). The aim of this study was to model the risk factors for dyslipidemia and blood lipid indices.

METHODS

This study was conducted based on the data collected in the initial phase of Ravansar cohort study (2014-16). At the beginning, all the 453 available variables were examined in 33 stages of sensitivity analysis by perceptron Artificial Neural Network (ANN) data mining model. In each stage, the variables that were more important in the diagnosis of dyslipidemia were identified. The relationship among the variables was investigated using stepwise regression. The data obtained were analyzed in SPSS software version 25, at 0.05 level of significance.

RESULTS

Forty percent of the subjects were diagnosed with lipid disorder. ANN identified 12 predictor variables for dyslipidemia related to nutrition and physical status. Alkaline phosphatase, Fat Free Mass (FFM) index, and Hemoglobin (HGB) had a significant relationship with all the seven blood lipid markers. The Waist Hip Ratio was the most effective variable that showed a stronger correlation with cholesterol and Low-Density Lipid (LDL). The FFM index had the greatest effect on triglyceride, High-Density Lipid (HDL), cholesterol/HDL, triglyceride/HDL, and LDL/HDL. The greatest coefficients of determination pertained to the triglyceride/HDL (0.203) and cholesterol/HDL (0.188) model with nine variables and the LDL/HDL (0.180) model with eight variables.

CONCLUSION

According to the results, alkaline phosphatase, FFM index, and HGB were three common predictor variables for all the blood lipid markers. Specialists should focus on controlling these factors in order to gain greater control over blood lipid markers.

Why are serum magnesium levels lower in Saudi dialysis patients?

Objectives

Serum magnesium (Mg) levels are often altered in dialysis patients. This study was conducted to ascertain the trends in Mg levels in patients on dialysis treatment.

Methods

A retrospective study was performed in the Dialysis Unit of King Khalid University Hospital, King Saud University, Riyadh, on patients undergoing regular dialysis. Patient demographic data, including body mass index (BMI), serum calcium (Ca), Mg, parathyroid hormone (PTH), cholesterol, and triglycerides were documented.

Results

Of a total of 115 patients, 70 (60.9%) were on haemodialysis (HD), and 45 (39.1%) were on peritoneal dialysis (PD). Of these, 10 patients (8.7%) had Mg levels of <0.7 mmol/L, 13 (11.3%) had 0.7 mmol/L, 24 (20.9%) had 0.8 mmol/L, 26 (22.6%) had 0.9 mmol/L, 16 (13.9%) 1.0 mmol/L, and 26 (23.9%) showed levels of ≥1.1 mmol/L. Approximately 93.0% had increased PTH levels, 43 (37.4%) had decreased serum Ca, 24 (20.9%) had low serum cholesterol, and 60 (52.2%) had low serum triglyceride. PD patients had significantly lower Mg and higher PTH levels compared to HD patients.

Conclusion

Patients with chronic kidney disease are generally considered at risk of developing hypermagnesaemia due to reduced renal excretion. However, a considerable number of dialysis patients in our unit had hypomagnesaemia (or low levels) instead. In addition to other factors, PTH secretion is affected by serum Mg levels. We found a significant correlation between serum Mg and Ca as well as PTH levels. Consequently, optimizing Mg concentration in patients on dialysate is essential to reduce risk of dyslipidaemia, arrhythmias, hyperparathyroidism, or adynamic bone disease.